|
1
|
Bhatia S, Tykodi SS, Lee SM and Thompson
JA: Systemic therapy of metastatic melanoma: On the road to cure.
Oncology (Williston Park). 29:126–135. 2015.
|
|
2
|
Dummer R and Flaherty KT: Resistance
patterns with tyrosine kinase inhibitors in melanoma: New insights.
Curr Opin Oncol. 24:150–154. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Long GV, Stroyakovskiy D, Gogas H,
Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A,
Grob JJ, et al: Combined BRAF and MEK inhibition versus BRAF
inhibition alone in melanoma. N Engl J Med. 371:1877–1888. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Hunter T and Cooper JA: Protein-tyrosine
kinases. Annu Rev Biochem. 54:897–930. 1985. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Cicenas J and Valius M: The CDK inhibitors
in cancer research and therapy. J Cancer Res Clin Oncol.
137:1409–1418. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Diaz-Padilla I, Siu LL and Duran I:
Cyclin-dependent kinase inhibitors as potential targeted anticancer
agents. Invest New Drugs. 27:586–594. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Malumbres M and Barbacid M: Cell cycle,
CDKs and cancer: A changing paradigm. Nat Rev Cancer. 9:153–166.
2009. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Malumbres M and Barbacid M: Cell cycle
kinases in cancer. Curr Opin Genet Dev. 17:60–65. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lapenna S and Giordano A: Cell cycle
kinases as therapeutic targets for cancer. Nat Rev Drug Discov.
8:547–566. 2009. View
Article : Google Scholar : PubMed/NCBI
|
|
10
|
Sharpless E and Chin L: The INK4a/ARF
locus and melanoma. Oncogene. 22:3092–3098. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Jonsson A, Tuominen R, Grafström E,
Hansson J and Egyhazi S: High frequency of p16(INK4A) promoter
methylation in NRAS-mutated cutaneous melanoma. J Invest Dermatol.
130:2809–2817. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Smalley KS, Lioni M, Dalla Palma M, Xiao
M, Desai B, Egyhazi S, Hansson J, Wu H, King AJ, Van Belle P, et
al: Increased cyclin D1 expression can mediate BRAF inhibitor
resistance in BRAF V600E-mutated melanomas. Mol Cancer Ther.
7:2876–2883. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Sausville EA: Complexities in the
development of cyclin-dependent kinase inhibitor drugs. Trends Mol
Med. 8(Suppl): S32–S37. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lee JH, Choi JW and Kim YS: Frequencies of
BRAF and NRAS mutations are different in histological types and
sites of origin of cutaneous melanoma: A meta-analysis. Br J
Dermatol. 164:776–784. 2011. View Article : Google Scholar
|
|
15
|
Meier F, Schittek B, Busch S, Garbe C,
Smalley K, Satyamoorthy K, Li G and Herlyn M: The RAS/RAF/MEK/ERK
and PI3K/AKT signaling pathways present molecular targets for the
effective treatment of advanced melanoma. Front Biosci.
10:2986–3001. 2005. View
Article : Google Scholar : PubMed/NCBI
|
|
16
|
Harper JW and Adams PD: Cyclin-dependent
kinases. Chem Rev. 101:2511–2526. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Walker GJ, Flores JF, Glendening JM, Lin
AH, Markl ID and Fountain JW: Virtually 100% of melanoma cell lines
harbor alterations at the DNA level within CDKN2A, CDKN2B, or one
of their downstream targets. Genes Chromosomes Cancer. 22:157–163.
1998. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ibrahim N and Haluska FG: Molecular
pathogenesis of cutaneous melanocytic neoplasms. Annu Rev Pathol.
4:551–579. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Curtin JA, Fridlyand J, Kageshita T, Patel
HN, Busam KJ, Kutzner H, Cho KH, Aiba S, Bröcker EB, LeBoit PE, et
al: Distinct sets of genetic alterations in melanoma. N Engl J Med.
353:2135–2147. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Roll DM, Ireland CM, Lu HSM and Clardy J:
Fascaplysin, an unusual antimicrobial pigment from the marine
sponge Fascaplysinopsis Sp. J Org Chem. 53:3276–3278. 1988.
View Article : Google Scholar
|
|
21
|
Soni R, Muller L, Furet P, Schoepfer J,
Stephan C, Zumstein-Mecker S, Fretz H and Chaudhuri B: Inhibition
of cyclin-dependent kinase 4 (Cdk4) by fascaplysin, a marine
natural product. Biochem Biophys Res Commun. 275:877–884. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Shafiq MI, Steinbrecher T and Schmid R:
Fascaplysin as a specific inhibitor for CDK4: Insights from
molecular modelling. PLoS One. 7:e426122012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Yan X, Chen H, Lu X, Wang F, Xu W, Jin H
and Zhu P: Fascaplysin exert anti-tumor effects through apoptotic
and anti-angiogenesis pathways in sarcoma mice model. Eur J Pharm
Sci. 43:251–259. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Segraves NL, Robinson SJ, Garcia D, Said
SA, Fu X, Schmitz FJ, Pietraszkiewicz H, Valeriote FA and Crews P:
Comparison of fascaplysin and related alkaloids: A study of
structures, cytotoxicities, and sources. J Nat Prod. 67:783–792.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
McArthur AG, Young RJ, Sheppard KE, Mar V,
Waldeck K, Fox SB, Kelleher FC, Liu W, Dobrovic A, Pearson R, et
al: Clinical significance of genomic alterations of the
CDK4-pathway and sensitivity to the CDK4 inhibitor PD0332991 in
melanoma. J Clin Oncol. 30:85202012.
|
|
26
|
Herlyn M, Balaban G, Bennicelli J, Guerry
D IV, Halaban R, Herlyn D, Elder DE, Maul GG, Steplewski Z, Nowell
PC, et al: Primary melanoma cells of the vertical growth phase:
Similarities to metastatic cells. J Natl Cancer Inst. 74:283–289.
1985.PubMed/NCBI
|
|
27
|
Lu XL, Zheng YL, Chen HM, Yan XJ, Wang F
and Xu WF: Anti-proliferation of human cervical cancer HeLa cell
line by fascaplysin through apoptosis induction. Yao Xue Xue Bao.
44:980–986. 2009.(In Chinese).
|
|
28
|
Fry DW, Harvey PJ, Keller PR, Elliott WL,
Meade M, Trachet E, Albassam M, Zheng X, Leopold WR, Pryer NK, et
al: Specific inhibition of cyclin-dependent kinase 4/6 by PD
0332991 and associated antitumor activity in human tumor
xenografts. Mol Cancer Ther. 3:1427–1438. 2004.PubMed/NCBI
|
|
29
|
Finn RS, Dering J, Conklin D, Kalous O,
Cohen DJ, Desai AJ, Ginther C, Atefi M, Chen I, Fowst C, et al: PD
0332991, a selective cyclin D kinase 4/6 inhibitor, preferentially
inhibits proliferation of luminal estrogen receptor-positive human
breast cancer cell lines in vitro. Breast Cancer Res. 11:R772009.
View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Sanchez-Martinez C, Gelbert L, Shannon H,
De Dios A, Staton BA, Ajamie RT, Sawada G, Wishart GN and Raub TJ:
LY2835219, a potent oral inhibitor of the cyclin-dependent kinases
4 and 6 (CDK4/6) that crosses the blood-brain barrier and
demonstrates in vivo activity against intracranial human brain
tumor xenografts. Mol Cancer Ther. 10:B2342011. View Article : Google Scholar
|
|
31
|
Walsh N, Kennedy S, Larkin AM,
Tryfonopoulos D, Eustace AJ, Mahgoub T, Conway C, Oglesby I,
Collins D, Ballot J, et al: Membrane transport proteins in human
melanoma: Associations with tumour aggressiveness and metastasis.
Br J Cancer. 102:1157–1162. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Young RJ, Waldeck K, Martin C, Foo JH,
Cameron DP, Kirby L, Do H, Mitchell C, Cullinane C, Liu W, et al:
Loss of CDKN2A expression is a frequent event in primary invasive
melanoma and correlates with sensitivity to the CDK4/6 inhibitor
PD0332991 in melanoma cell lines. Pigment Cell Melanoma Res.
27:590–600. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Hörmann A, Chaudhuri B and Fretz H: DNA
binding properties of the marine sponge pigment fascaplysin. Bioorg
Med Chem. 9:917–921. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Jalili A, Wagner C, Pashenkov M, Pathria
G, Mertz KD, Widlund HR, Lupien M, Brunet JP, Golub TR, Stingl G,
et al: Dual suppression of the cyclin-dependent kinase inhibitors
CDKN2C and CDKN1A in human melanoma. J Natl Cancer Inst.
104:1673–1679. 2012. View Article : Google Scholar : PubMed/NCBI
|
